Phase 2 N=7 Trial of Cannabis for Essential Tremor
Essential Tremor
Primary: Digital Spirography — 1.04; 1.00 millimeters of tremor amplitude
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
COVID-19
Primary: Change From Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA for AT-527 550 mg and Matched Placebo — -1.16; -1.26; -2.42…
Phase 2 N=58 AXS-05 Phase II Trial on Smoking Behavior
Smoking Cessation · Smoking, Cigarette · Nicotine Dependence
Primary: Change in Smoking Intensity — -8.49; -6.79 change in cigarettes per day — p=0.05
Phase 2 N=50 Sarilumab for Patients With Moderate COVID-19 Disease
COVID
Primary: Number of Participants With Intubation or Death — 5; 1 Participants
Phase 2 N=110 Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
Parkinson Disease
Primary: Change in Motor Function During Levodopa Withdrawal. — -4.210; -5.114 score on a scale
Phase 2 N=30 Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Clinical Response — 0; 3; 7; 19 Participants
Phase 2 N=354 A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.
Diabetic Macular Edema
Primary: Change in Best Corrected Visual Acuity (BCVA) — 1.0; 0.8; 0.9; 2.5 Letters Correctly Read — p=0.16
Phase 2 N=321 Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
Atopic Dermatitis
Primary: Proportion of Patients Achieving an Investigators Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA in Treated…
Phase 2 N=7 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
Phase 2 N=21 Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Chronic Lymphocytic Leukemia (CLL)
Primary: Complete Response — 45 Percentage of Participants
Phase 2 N=122 Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis Eczema
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 4; 0; 0 Participants
Phase 2 N=56 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT) — 2; 1; 2; 0 Participants
Phase 2 N=100 Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
COVID-19
Primary: All-Cause Mortality Rate Through Day 29 — 28.0; 32.0 Percentage of participants — p=0.8275
Phase 2 N=327 Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)
Atopic Dermatitis
Primary: Change From Baseline in Numeric Rating Scale (NRS) for Pruritus in Treated Population Compared to Vehicle Population at Week 8 — -3.8; -2.9; -2.9 score on a scale…
Phase 2 N=4 Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
Alcohol Disorders
Primary: Percent Abstinent Days — 3.13; 100 Percentage of days